Multiple Myeloma

A panel of experts review real-world clinical scenarios to highlight recent advances in the management of multiple myeloma.

Overall survival was significantly improved when elotuzumab was added to pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and proteasome inhibitors

An expert describes how he determines treatment duration and discontinuation for transplant-ineligible multiple myeloma in his clinical practice.

Luciano Costa, MD, PhD, discusses his maintenance therapy strategies for patients with transplant-ineligible multiple myeloma.

Rafael Fonseca, MD, spoke about how bispecific antibodies like elranatamab have the potential to change the treatment paradigm for patients with relapsed/refractory multiple myeloma.

The European Commission has announced the first global approval of teclistamab for previously treated relapsed/refractory multiple myeloma following its conditional marketing authorization.

Dr Rafael Fonesca illustrates how he selects therapies for patients with transplant-ineligible multiple myeloma based on real-world evidence.

A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.

A real-world, prospective cohort study identified independent predictors may increase the risk of early mortality in patients with newly diagnosed multiple myeloma.

Paul G. Richardson, MD, presented data from the phase 3 DETERMINATION study at 2022 ASCO and theorized how these findings could extend to similar regimens in newly diagnosed multiple myeloma.

Rafael Fonseca, MD, describes key data from the MAIA and SWOG 0777 studies investigating triplet regimens in multiple myeloma treatment, and how the results compare.

Dr Luciano Costa provides an overview of the currently available treatment options for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Rafael Fonseca, MD, discusses use of elranatamab in patients with relapsed/refractory multiple myeloma and ongoing research into bispecific antibodies.

Paul G. Richardson, MD, looks at MRD data from the DETERMINATION study for its potential to guide treatment selection in newly diagnosed multiple myeloma.

Results from a phase 2 study indicated that adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone with a minimal residual disease–adapted design boosted responses for those with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, spoke about key takeaways from the phase 1/2 SWOG 1211 trial and top research presented at ASCO 2022 in multiple myeloma.

Elotuzumab, lenalidomide, high-dose melphalan, as well as umbilical cord blood–derived natural killer cells and autologous stem cell transplant demonstrated tolerability and improved transplant outcomes for high-risk multiple myeloma.

Paul G. Richardson, MD, uses results of the DETERMINATION study that were presented at 2022 ASCO to justify choice of appropriate therapy for individual patients with treatment-naïve multiple myeloma.

Patients with relapsed/refractory multiple myeloma appear to benefit from treatment with teclistamab, which was given a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Patients in Europe who have multiple myeloma and have received at least 1 previous therapy can now receive treatment with selinexor plus bortezomib and low-dose dexamethasone following its full marketing authorization by the European Commission.

Post-marketing surveillance data further confirmed carfilzomib to be a well-tolerated and promising option among patients with relapsed/refractory multiple myeloma, although investigators emphasize the importance of watching for cardiac comorbidities.

Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.

Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.

Saad Z. Usmani, MD, MBA, FACP, spoke about the safety profile of standard triplet therapy with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma in the phase 3 SWOG 1211 trial and how results of this trial may be used in future datasets to inform treatment in this setting.

C. Ola Landgren, MD, PhD, discusses progression-free survival data from the phase 3 DETERMINATION trial examining lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplant plus continuous lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Kimberley R. Doucette, MD, MSC; and David H. Vesole, MD, PhD, discuss updates to frontline treatment in multiple myeloma.

Sarah A. Holstein, MD, PhD, reviews updated treatment options for patients with newly diagnosed multiple myeloma.

“What is more gratifying than people who are alive in complete remission for years?...The therapeutics are so effective and the symptoms of myeloma can be so rapidly reversed. It’s really gratifying.”

At 2022 ASCO, Paul G. Richardson, MD, dives into results of the DETERMINATION study, which examined triplet therapy with lenalidomide plus either lenalidomide maintenance until progression or autologous stem transplantation in newly diagnosed multiple myeloma.

Comprehensive perspectives on the role of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma.